QHSLab (USAQ)
OTHER OTC:USAQ
Want to see USAQ full AI Analyst Report?
USAQ Stock Chart & Stats
$0.49
-$0.04(-14.29%)
At close: 4:00 PM EST
$0.49
-$0.04(-14.29%)
Day’s Range― - ―
52-Week Range$0.08 - $1.14
Previous CloseN/A
Volume38.37K
Average Volume (3M)6.57K
Market Cap
$8.50M
Enterprise Value$6.72M
Total Cash (Recent Filing)$362.09K
Total Debt (Recent Filing)$130.18K
Price to Earnings (P/E)12.6
Beta0.87
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.04
Shares Outstanding15,032,788
10 Day Avg. Volume9,209
30 Day Avg. Volume6,568
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)4.21
Price to Sales (P/S)2.54
P/FCF Ratio38.43
Enterprise Value/Market Cap0.79
Enterprise Value/Revenue2.42
Enterprise Value/Gross Profit3.63
Enterprise Value/Ebitda9.81
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.3
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Profitability And MarginsMargin expansion to roughly 67% gross and 17% net with positive net income indicates the core offering and cost structure are delivering durable profitability. Sustained margins support reinvestment in product and sales, improve resilience to cyclical pressure, and enable multi‑quarter growth funding internally.
Deleveraged, Cleaner Balance SheetRecent deleveraging and positive equity reflect a cleaner capital structure, lowering refinancing and interest burden risks. This financial flexibility supports strategic investments, reduces near‑term solvency pressure, and makes multi‑quarter execution on recurring revenue initiatives more feasible without immediate external financing.
Product And Distribution Expansion Into Recurring CareLaunching a national representative network and expanding Q‑Connect adoption are structural moves to lower customer acquisition friction and drive recurring ISP revenue. Deeper clinical integration and programs (including GLP‑1 support) broaden addressable market and help convert one‑time sales into ongoing practice revenue streams.
Bears Say
Weak Cash Flow ConversionDespite reported profitability, cash generation is minimal and has deteriorated sharply versus the prior year. Poor cash conversion limits self‑funding for growth initiatives, increases reliance on external financing, and raises execution risk if cash flow does not reaccelerate over the next several quarters.
Historic Financial Volatility And Inconsistent Track RecordA history of multi‑year losses followed by a sharp swing to profit demonstrates inconsistent operating performance. This volatility complicates longer‑term forecasting, weakens stakeholder confidence, and increases the probability that operational setbacks could reappear during scaling or market shifts.
Very Small Operating FootprintAn employee base of only four suggests limited internal capacity to execute a national practice rollout and broaden product adoption. Small headcount raises key‑person risk, may constrain sales and implementation bandwidth, and could slow scaling unless management materially increases operating resources.
QHSLab News
USAQ FAQ
What was QHSLab’s price range in the past 12 months?
QHSLab lowest stock price was $0.08 and its highest was $1.14 in the past 12 months.
What is QHSLab’s market cap?
QHSLab’s market cap is $8.50M.
When is QHSLab’s upcoming earnings report date?
QHSLab’s upcoming earnings report date is Aug 19, 2026 which is in 75 days.
How were QHSLab’s earnings last quarter?
Currently, no data Available
Is QHSLab overvalued?
According to Wall Street analysts QHSLab’s price is currently Overvalued.
Does QHSLab pay dividends?
QHSLab does not currently pay dividends.
What is QHSLab’s EPS estimate?
QHSLab’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does QHSLab have?
QHSLab has 15,032,788 shares outstanding.
What happened to QHSLab’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of QHSLab?
Currently, no hedge funds are holding shares in USAQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
QHSLab
QHSLab, Inc., a medical device technology and software as a service (SaaS) company, focuses on value-based healthcare, informatics, and algorithmic personalized medicine. It also develops digital therapeutics and point of care solutions to support remote patient monitoring, address chronic care, and preventive medicine. In addition, the company provides quality health score lab expert system (QHSLab), a cloud-based SaaS system, which provides physicians and healthcare organizations with the ability to capture and store patient information electronically in a secure database; and distributes AllergiEnd, a diagnostic related product and allergen immunotherapy treatments to primary care physicians. Its products are designed to promote prevention, early detection, management, and reversal of chronic diseases. The company was formerly known as USA Equities Corp. and changed its name to QHSLab, Inc. in April 2022. QHSLab, Inc. has a strategic alliance with Medical License Factory, LLC. The company was incorporated in 1983 and is based in West Palm Beach, Florida.